PANTOCALCIN [Hopantenic acid]
Pantocalcin is a nootropic drug that is used in the treatment of various neurotic disorders and psychoemotional stress. The active ingredient of this drug is Hopantenic acid and it has neuroprotective, neurometabolic and neurotrophic properties.
Hopantenic acid (N-pantoyl-GABA) is the higher homologue of D(+)-pantoyl–g– aminobutyric acid (vitamin B5), in which β-Alanine is replaced by γ-aminobutyric acid (GABA).
Indications for use:
Many Russian physicians prescribe Pantocalcine to children as a mild nootropic for correction of ADHD and other conditions.
The on-label use of Pantocalcin includes the following indications (as a part of complex therapy):
- cognitive impairment in organic brain lesions and neurotic disorders;
- cerebrovascular insufficiency caused by atherosclerotic changes in cerebral vessels, senile dementia (initial form) and residual organic brain lesions in persons of mature age and in the elderly;
- cerebral organic insufficiency in patients with schizophrenia;
- extrapyramidal hyperkinesis in patients with hereditary diseases of the nervous system (Huntington's chorea, hepatocerebral dystrophy, Parkinson's disease, etc.);
- correction of side effects caused by neuroleptics or preventively as a so-called “add-back therapy”;
- psychoemotional stress, reduced mental and physical performance as well as problems with concentration and memory;
The drug improves glucose utilization (especially in the cerebral cortex, subcortical ganglia, hypothalamus and cerebellum), nucleic acid metabolism; it also activates the synthesis of ATP, protein and RNA, i.e. stimulates anabolic processes in the brain neurons. The indirect neurometabolic effect of the drug is associated with the improvement of microcirculation in the brain due to optimization of the passage of red blood cells through the vessels of the microvasculature and inhibition of platelet aggregation. Along with the neurometabolic effect the drug has antihypoxic (reducing neuronal oxygen demand under hypoxic conditions), neuroprotective (increasing resistance of nerve cells to adverse factors of various origins) and antiepileptic effects.
active ingredient: hopantenic acid (hopantenic acid or calcium salt of hopantenic acid) 250 mg and 500 mg;
Pantocalcin is rapidly absorbed from the gastrointestinal tract. Tmax in blood plasma is 1 hour. The highest concentrations are found in liver, kidneys, stomach wall and skin. The drug penetrates the blood-brain barrier. Pantocalcin is not metabolized in the body and is excreted unchanged within 48 hours (67.5% of the dose with urine and 28.5% fecally).
Dosage and administration:
Orally, 15-30 minutes after meals.
As a performance enhancer, Pantocalcin should be taken in a dose of 0.25g, 3 times a day.
Single dose for adults is 0.5-1g, for children – 0.25-0.5g; daily dose for adults is 1.5-3g, for children – 0.75-3g.
Duration of treatment lasts from 1 to 4 months, in some cases it can last up to 6 months. After 3-6 months it is possible to repeat the course of treatment.
Adults with urination disorder should take 0.5-1g 2-3 times a day; children should take 0.25-0.5g. Duration of treatment is from 2 weeks to 3 months; the duration depends on the disorder severity and therapeutic effects.
As a correction of neuroinfection and traumatic brain injury consequences.
- acute renal failure;
- pregnancy (I trimester).
- allergic reactions.
Interaction with other drugs:
Pantocalcin prolongs the effects of barbiturates and enhances the effects of anticonvulsant drugs, nootropic drugs and central nervous system stimulants; therefore, precautions should be taken to ensure that the combined use of these drugs with Pantocalcine will not result in any additional side effects.
Pantocaltcin might mitigate the side effects of phenobarbital, finlepsin and antipsychotics.
Pantocalcin effects can be increased if the drug is combined with glycine or xydifon.